Threshold analysis of Helicobacter pylori therapy

Area of Science:

• Gastroenterology
• Pharmacoeconomics
• Clinical Decision-Making

Background:

• Conflicting clinical guidelines exist regarding the use of antibacterials for Helicobacter pylori (H. pylori) eradication.
• Discrepancies in recommendations necessitate a clear framework for treatment decisions in patients with upper gastrointestinal symptoms.

Purpose of the Study:

• To analyze the basis for conflicting recommendations on antibacterial therapy for H. pylori eradication.
• To model the decision-making process for antibacterial treatment using threshold analysis.

Main Methods:

• A threshold analysis model was employed to evaluate the decision for or against antibacterial therapy.
• The threshold represents the minimum probability of a diagnosis for which antibacterial therapy offers a better expected outcome.
• Low threshold values indicate a strong indication for antibacterial intervention.

Main Results:

• For suspected peptic ulcer disease, antibacterial therapy is favorable (threshold <35%) due to high success and low cost.
• In NSAID-associated ulcer patients, the threshold is 73% based on success rates but drops to 7% when considering costs.
• For non-ulcer dyspepsia, the threshold is high (76%) based on success but low (16%) when factoring in marginal costs.

Conclusions:

• Prioritizing therapeutic success suggests avoiding antibacterial therapy for vague symptoms unless H. pylori is confirmed.
• If healthcare costs are the primary driver, empirical antibacterial therapy may be justified regardless of confirmed H. pylori role.
• The analysis highlights the differential impact of cost and efficacy on treatment recommendations for H. pylori.